Astellas Pharma has reported data from the Phase III GATHER2 clinical trial where Izervay [avacincaptad pegol (ACP) intravitreal solution] reduced geographic atrophy (GA) lesion growth rate in individuals with GA secondary to age-related macular degeneration (AMD).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,